Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference on February 7-8, 2024, in New York. CEO Mark J. Foley will be participating in a fireside chat on February 8 at 9:30a.m. EST. The live audio webcast will be available on the company's website, with a replay available for approximately 90 days.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6^th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thursday, February 8, at 9:30a.m. EST.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, https://hcp.daxxifytherapy.com/, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201633021/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Cathryn Castaldo, 615-245-7567

cathryn.castaldo@revance.com

Source: Revance Therapeutics, Inc.

FAQ

When is the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference taking place?

The conference is scheduled for February 7-8, 2024, in New York, New York.

Who will be participating in the fireside chat at the conference?

CEO Mark J. Foley will be participating in the fireside chat on February 8 at 9:30a.m. EST.

Where can interested parties access the live audio webcast for the conference?

The live audio webcast will be available on the Investor Relations section of the company's website at www.revance.com.

How long will the webcast replay be available after the live presentation?

The webcast replay will be available for approximately 90 days after the conclusion of the live presentation.